SuperworthArq ARQ
- Market cap
- $76.4M
- PE
- n/m
- a loss over the last year
- Forward PE
- n/m
- not a meaningful number
- Price to sales
- 0.6×
- EV/EBIT
- n/m
- a loss over the last year
- Revenue, 12 months
- $123.4M
- +5% on a year ago
- Net margin
- −42.3%
- Free cash flow yield
- −6.6%
Arq trades at 0.6× sales. Its trailing earnings are negative, so it has no PE. Revenue was $123.4M over the last twelve months, up 5% on a year earlier with a −42% net margin.
Charts
Financials
| Income statement | Q3 FY23 | Q4 FY23 | Q1 FY24 | Q2 FY24 | Q3 FY24 | Q4 FY24 | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| $29.8M+5% | $28.1M+20% | $21.7M+5% | $25.4M+24% | $34.8M+17% | $27M−4% | $27.2M+25% | $28.6M+13% | $35.1M+1% | $29.4M+9% | $29.1M+7% | $29.9M+5% | |
| Cost of revenue | $20.7M−4% | $14.1M−19% | $13.7M−20% | $17.2M+12% | $21.3M+3% | $17.2M+22% | $17.3M+26% | $19.1M+11% | $25M+17% | $25.4M+48% | $19.1M+10% | $18.4M−4% |
| Gross profit | $9.1M+33% | $14M+136% | $8M+121% | $8.2M+60% | $13.4M+47% | $9.8M−30% | $9.9M+24% | $9.5M+16% | $10.1M−25% | $4M−59% | $9.9M+0% | $11.5M+21% |
| R&D | $639K | $1.2M | $1.6M+122% | $929K+20% | $787K+23% | $709K−39% | $874K−46% | $2.7M+190% | $2.6M+226% | $1.2M+69% | $982K+12% | $958K−65% |
| SG&A | $8.3M+353% | $6.5M+162% | $7.7M−32% | $7M−12% | $8.1M−3% | $6M−8% | $6.1M−21% | $5.9M−16% | $4.6M−43% | $6M+0% | $7.4M+22% | $6.8M+15% |
| −$2.5M−4% | $3.1M | −$3M−62% | −$1.4M−77% | $2M | $413K−87% | $662K | −$1.8M+26% | −$839K | −$51.2M | −$982K | −$68K−96% | |
| Interest expense | $787K+848% | $859K+1016% | $791K+48% | $829K−1% | $806K+2% | $831K−3% | $724K−9% | $594K−28% | $587K−27% | $544K−35% | $705K−3% | $748K+26% |
| Pre-tax income | −$2.2M−9% | $3.5M | −$3.4M−55% | −$1.9M−67% | $1.6M | −$1.5M | $203K | −$2.4M+22% | −$653K | −$50M+3163% | −$842K | −$733K−69% |
| $0 | $186K−11% | $0 | $30K | $0 | −$194K | $0 | $0 | $0 | $12K | $0 | $0 | |
| Net income | −$2.2M−9% | $3.3M | −$3.4M−55% | −$2M−66% | $1.6M | −$1.3M | $203K | −$2.4M+20% | −$653K | −$50M+3636% | −$842K | −$733K−69% |
| −$0.07−46% | $0.11 | −$0.09−72% | −$0.06−71% | $0.04 | −$0.03 | $0.00 | −$0.06+0% | −$0.02 | −$1.20+3900% | −$0.02 | −$0.02−67% | |
| 31.8M+72% | 32.7M+77% | 37.1M+56% | 34.4M+26% | 37.4M+18% | 41.9M+28% | 42.5M+15% | 41.5M+21% | 41.6M+11% | 41.7M−1% | 41.7M−2% | 42.1M+1% |
Revenue: Q1 FY12: 6 months less the 3 months printed beside them.
Cost of revenue: Q1 FY12 and Q1 FY13: 6 months less the 3 months printed beside them.
Gross profit: Q1 FY12 and Q1 FY13: 6 months less the 3 months printed beside them. 46 periods, Q1 FY14 to Q2 FY26: not printed by the filing, worked out from its own lines.
R&D: Q1 FY12 and Q1 FY13: 6 months less the 3 months printed beside them.
SG&A: Q1 FY12 and Q1 FY13: 6 months less the 3 months printed beside them.
Operating income: Q1 FY12: 6 months less the 3 months printed beside them.
Interest expense: Q1 FY12 and Q1 FY13: 6 months less the 3 months printed beside them.
Pre-tax income: Q1 FY12: 6 months less the 3 months printed beside them.
Net income: Q1 FY12: 6 months less the 3 months printed beside them.
EPS, diluted: 7 periods, Q1 FY12 to Q4 FY25: quarter's net income to common over its shares, to the cent.
Diluted shares: Q1 FY12: share-days: the 6-month average less the second quarter's. Q2 FY12: not printed by the filing, worked out from its own lines. Q4 FY12: a loss quarter: its basic count, share-days: the 12-month average over 366 days less the 9-month over 274, the two on one basis (x1.977). Q4 FY13: a loss quarter: its basic count, share-days: the 12-month average over 365 days less the 9-month over 273, the two on one basis (x1.977). 3 periods, Q4 FY22 to Q4 FY25: a loss quarter: its basic count, share-days: the 12-month average less the 9-month, weighted by days. Q4 FY23: share-days: the 12-month average less the 9-month, weighted by days.
From each company's 10-Q and 10-K filings, the newest version of each figure. Quarters are as filed (a fourth quarter is the year less its first nine months), fiscal years as the 10-K prints them, restated where a later 10-K restated them, and balance sheet lines as of the period's end. A quarter whose 10-Q isn't filed yet is from the company's results release. Growth is on the same period a year earlier. A dash is a period with no figure for the line: the filing doesn't print it, or it hasn't been read yet.
Peers
Companies in Chemicals nearest Arq's size, closest first.
| Company | Market cap | PE | Its 10y median PE | Fwd PE | P/S | Revenue growth | Net margin |
|---|---|---|---|---|---|---|---|
| ARQArq | $76.4M | n/m | 11.4× | 0.6× | +5% | −42.3% | |
| FTLFFitlife Brands | $78.4M | 13.5× | 15.3× | 0.8× | +61% | 6.2% | |
| BTMDbiote | $38.4M | 10.7× | 12.3× | 0.2× | −8% | 3.2% | |
| NAGENiagen Bioscience | $192.3M | 13.5× | 27.0× | 1.5× | +11% | 12.4% | |
| Peer median | $78.4M | 13.5× | 15.3× | 0.8× | +11% | 6.2% |
More on Arq
Each number over time
- PE ratio
- Price to sales ratio
- EV/EBIT
- Price to free cash flow
- Price to book ratio
- Market cap
- Revenue
- EPS
- Free cash flow
- Profit margin
- Shares outstanding
Its groups
About
- Industry
- Chemicals
- Sector
- Basic Materials
Valuation data, not investment advice. Prices as of .